The improvement in survival caused by EGFR‐TKIs in patients with an EGFR‐mutant lung cancer, and the propensity of these cancers to lead to a metastatic brain tumor, may contribute to this phenomenon (Matsumoto et al., 2006). This evidence concerns the gene EGFR and lung carcinoma.